Mefenamic acid linked to DRESS Syndrome: IPC Drug Safety alert
The Indian Pharmacopoeia Commission (IPC), through its recently issued drug safety alert for the month of November, has revealed that a non-steroidal anti-inflammatory agent Mefenamic Acid, indicated for the treatment of mild to moderate pain, and primary dysmenorrhea, is linked with adverse drug reactions (ADRs) named Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome.
For more details, check out the link given below:
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd